On September 21, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, reported that results from a clinical phase I study of the drug candidate ADC-1013 (JNJ-64457107) will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, US (Press release, Alligator Bioscience, SEP 21, 2017, View Source [SID1234538685]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alligator Bioscience will give both an oral and poster presentation at the SITC (Free SITC Whitepaper) conference with the title: "First-in-human study with intratumoral administration of a CD40 agonistic antibody: preliminary results with ADC-1013/JNJ-64457107 in advanced solid malignancies". The oral presentation will be held at Session Clinical Trials: New Agents, starting at 1:45 p.m. ET (7:45 p.m. CET) on November 10, 2017.
For further information about the program, please visit the conference web site:
View Source
For further information:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: [email protected].
This release contains information that Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on 21 September 2017.
Notes to editors
About ADC-1013
ADC-1013 is a drug candidate intended for immunotherapy of different types of cancer. Pre-clinical data have shown that the ADC-1013 antibody effectively activates T-cells, mediated through binding to the co-stimulatory receptor CD40 on dendritic cells. The increased T cell activation enables the immune system to attack the cancer. In addition, since some cancer cells express CD40 on the surface, ADC-1013 may act also through a secondary mechanism of action killing cancer cells directly.
In August 2015, Alligator licensed global development rights for ADC-1013 to Janssen Biotech Inc. In October 2016, Janssen Biotech, Inc. started a second phase I clinical study (ClinicalTrials: NCT02829099). That study is an intravenous dose escalation study with ADC-1013 (JNJ-64457107).
About the ADC-1013 clinical Phase I study
The study to be presented is a multicenter, open-label phase I study in patients with advanced solid tumors evaluating safety and tolerability, pharmacokinetics, immunogenicity, biomarker response and clinical response. The study is a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five hospitals in Sweden, Denmark and the UK. The study was performed by Alligator and includes 24 patients and ten different tumor types. For further information, please visit View Source; NCT02379741.